Haleon H1 2026: Organic Growth 2.6%, Adjusted EPS +12%, £457M Buyback Executed
HLN sits 15% above its 52-week low of $8.65 on elevated volume (2.8× avg).
Summary
Haleon reported H1 2026 organic revenue growth of 2.6% and adjusted diluted EPS of 10.3p, up 12%. The company completed £457M of its £500M buyback, raised the interim dividend 9%, and reaffirmed full-year guidance.
Key Events · Earnings and Guidance · HLN
-
H1 2026 Results Beat
Revenue reached £5,602m, with organic growth of 2.6% (2.1% from price, 0.5% from volume/mix). Adjusted operating profit came in at £1,364m, up 8.2% at constant currency, while adjusted diluted EPS rose 12.0% to 10.3p.
-
Shareholder Returns
Of the £500m 2026 buyback, £457m has been completed. The interim dividend was raised 9% to 2.4p per share, payable on 17 September 2026.
-
FY 2026 Guidance Reaffirmed
Organic revenue growth is expected to be 3-5%, with high single-digit adjusted operating profit growth at constant currency. Net interest is projected at approximately £255m, and the adjusted effective tax rate at about 24.5%.
-
Restructuring Charge
A £168m charge for the operating model transformation is expected to deliver £175m-200m in annualised gross savings over two years, with one-third of that realised in 2026.
Analysis · HLN · Industrial Applications And Services
A solid first half saw Haleon deliver 2.6% organic revenue growth and a 12% jump in adjusted diluted EPS to 10.3p, powered by operating leverage and productivity gains. The company completed £457 million of its £500 million 2026 buyback, declared a 9% higher interim dividend, and reaffirmed full-year guidance. A £168 million restructuring charge tied to the new operating model is expected to yield £175-200 million in annual savings over two years. The results show a consumer health giant executing well in a challenging environment, with strong cash flow supporting shareholder returns.
At the time of this filing, HLN was trading at $9.97 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $44.7B. The 52-week trading range was $8.65 to $11.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.